Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPIC-PEDS: Nirmatrelvir/Ritonavir in Pediatric COVID-19
NCT05261139Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Mar 2022
- Primary completion
- Jul 2026
- Modality
- Orthosteric Ligands
- Countries
- 7
01
Overview
Phase 3, open-label trial of Nirmatrelvir in coronavirus disease 2019 (COVID-19) (5 cohorts), sponsored by Pfizer. Primary endpoints: Maximum Observed Plasma Concentration at Day 5, Area Under the Curve to the End of the Dosing Period at Day 5 and 2 more. Started Mar 2022; status: recruiting.
02
Drugs
Nirmatrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05261139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05261139.